Validation of Radio-induced Damage Biomarkers

Centre Hospitalier Universitaire de Saint Etienne16 enrolled

Overview

The aim of this study is to confirm in humans the relevance and the kinetics of radio-induced bio-markers in plasma and urines, previously described at the preclinical stage.

The nuclear and radiologic risks monitoring is a major preoccupation for our society. During an accident, it is primordial to define the biologic dosimetry. The dose and distribution knowledge is crucial for the medical care. Indeed, Total Body Irradiation (TBI) and Partial Body Irradiation (PBI) do not have the same clinical outcome. A Total Body Irradiation induces an acute radiation syndrome with a Medullary Aplasia. A quick diagnostic would allow the optimization of the medical care. Nowadays, the analyse of the chromosome with two centromeres is the current norm to estimate the radiation dose, but this technique is time consuming, and not adapted to an emergency situation, and to a large population. The new genetic techniques could permit the quick radiation dosimetry diagnosis. The research of early exposition bio-markers seems to be of a major interest. These bio-markers would allow to rapidly define the radiations perceived by an exposed subject, before the apparition of the symptoms, and by the way, to conduct to a therapeutic strategy more adapted to the patient. In this purpose, the present study will need blood and urines samples of patients totally or partially exposed to radiations, according to their usual medical care.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Bone Metastasis Malignant Hemopathy

Interventions

blood and urines samplesOTHER

For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy. Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * More than 18 years old * For the group A: Patient suffering from a malignant blood disease requiring a whole-body radiation, without (or prior to) a concomitant chemotherapy, according to the following protocol: 2x2 Gray per day, during 3 days. * OR For the group B: Patient with one (or more) pelvis metastasis requiring radiation therapy without concomitant chemotherapy, according to the following protocol: 4 Gray per day for 5 days. Exclusion Criteria: * More than 70 years old, * Subject presenting abnormal blood count (grade 3), * Person with a not controlled chronic illness, * Subject presenting an abnormal hepatic assessment (grade 3), * Subject having already received ionizing treatments, * Subject reached HIV, hepatitis C or any other progressive infectious diseases, * Pregnant women or nursing mothers, * Person under protection of justice or unable to give consent.

Locations (2)

Institut de Cancérologie Lucien Neuwirth

Saint-Priest-en-Jarez, France

Institut Gustave Roussy

Villejuif, France

Outcomes

Primary Outcomes

Level of haematological and biochemical markers

The following bio-markers levels will be calculated : * Blood count, * Pads, * Haemoglobin, * Serum iron, * Plasma urea, * Urinary urea * Total protein, * albumin * creatin kinase, * Aspartate Amino Transferase, * alkaline phosphatase, * Total cholesterol, * Triglycerides, * Plasma creatinine * Creatinine clearance, * Urinary creatinine * Blood glucose, * Citrulline, * erythropoietin, * Plasma amylase, * Myoglobin, * Troponin, * C reactive protein, * Rate of prothrombin, * Fibrinogen, * D-Dimer, * Factor-V, * Fms-like tyrosine kinase 3-Ligand.

Time frame: Day 3

Quantification of chromosomal aberrations

Quantification of chromosomal aberrations will be performed on the blood samples performed at days 0, 1, 2 and 3 after the beginning of the rays perform in the usual practice.

Time frame: Day 3

Detection of biochemical markers

The presence or absence of these markers will be notified: * Interleukin 1 * Interleukin 6 * Interleukin 8 * Interleukin 18 * Tumor Necrosis Factor alpha (TNF-alpha) * Brain-Derived Neurotrophic Factor (BDNF) * Granulocyte Colony-Stimulating Factor (G - CSF) * Serum amyloid A (SAA) * Growth Arrest and DNA Damage-inducible 45 (GADD45) * Intestinal-type Fatty Acid-Binding Protein (FABP-I) * Liver-type Fatty Acid-Binding Protein (L-FABP) * Heart-type Fatty Acid-Binding Protein (H-FABP) * Stem Cell Factor Receptor CD117

Time frame: Day 3

Metabolomics markers levels

The metabolomic levels of the following molecules will be calculated on urine samples: * 3 - Sulfate Hydroxytyrosol * 1, 6-Anhydro-beta-D-glucose * 1 - Methylnicotinamide * 2 - Hydroxyisobutyrate * 3 - aminoisobutyrate * 3 - hydroxyisovalerate * 3 - Hydroxymandelate * 3 - Indoxylsulfate * 4 - Hydroxyphenylacetate * Acetate * Acetone * Adipic acid * Alanine * Betaine * Carnitine * Choline * Cis-Aconitate * Citrate * Creatine * Creatinine * dimethylamine * Ethanolamine * Formats * Glucose * Glycine * Glycolate * Hippurate * Histidine * Hypoxanthine * Isethionic acid * Lactate * Methanol * Methylamine * N, N-Dimethylglycine * N - Acetylserotonin sulfate * N - Acetyltaurine * O - Acetylcarnitine * O - Phosphocholine * Pi-methylhistidine * Pyroglutamate * Succinate * Tartrate * Tau-methylhistidine * Taurine * Threonine * trans-Aconitate * Trigonelline * Trimethylamine N-oxide * Tyramine sulfate * Tyrosine * Tyrosol sulfate * Uracil * Robert acid * Valine * Xanthine

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Validation of Radio-induced Damage Biomarkers

Overview

Conditions

Interventions

Eligibility

Locations (2)

Outcomes

Primary Outcomes

Secondary Outcomes